up-to-date with a click!
Update April, 2018
 
Curated by Peter Lansberg,
a Dutch lipidologist and educator, and
reviewed by prof. Philip Barter, Past President of the
International Atherosclerosis Society.

The IAS Statin Newsletter will keep you up-to-date with all recent statin publications, using a curated approach to select relevant articles.

Statin publications April 2018

Other

  1. Navar AM, Pencina MJ, Mulder H et al. Improving patient risk communication: Translating cardiovascular risk into standardized risk percentiles. Am Heart J 2018; 198:18-24. http://www.ncbi.nlm.nih.gov/pubmed/?term=29653642
  2. Chen SK, Barbhaiya M, Fischer MA et al. Lipid Testing and Statin Prescription among Medicaid Recipients with Systemic Lupus Erythematosus, Diabetes Mellitus and the General Medicaid Population. Arthritis care & research 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29648687
  3. Shin EY, Ochuko P, Bhatt K et al. Errors in Electronic Health Record-Based Data Query of Statin Prescriptions in Patients With Coronary Artery Disease in a Large, Academic, Multispecialty Clinic Practice. J Am Heart Assoc 2018; 7. http://www.ncbi.nlm.nih.gov/pubmed/?term=29650707
  4. DeJonckheere M, Robinson CH, Evans L et al. Designing for Clinical Change: Creating an Intervention to Implement New Statin Guidelines in a Primary Care Clinic. JMIR human factors 2018; 5:e19. http://www.ncbi.nlm.nih.gov/pubmed/?term=29691206
  5. Shin D, Bohra C, Kongpakpaisarn K. Novel method versus the Friedewald method for estimating low-density lipoprotein cholesterol in determination of the eligibility for statin treatment for primary prevention in the United States. Medicine (Baltimore) 2018; 97:e0612. http://www.ncbi.nlm.nih.gov/pubmed/?term=29703063
  6. Iqbal K, Islam N, Azam I et al. Lack of association of statin use with vitamin D levels in a hospital based population of type 2 diabetes mellitus patients. Pak J Med Sci 2018; 34:204-208. http://www.ncbi.nlm.nih.gov/pubmed/?term=29643908

Add on treatments

  1. Thabit S, El Sayed NSE. Effect of pioglitazone and simvastatin in lipopolysaccharide-induced amyloidogenesis and cognitive impairment in mice: possible role of glutamatergic pathway and oxidative stress. Behavioural pharmacology 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29659380
  2. Bin Abdulhak AA, Robinson JG. Optimizing Statins and Ezetimibe in Guideline-Focused Management. Cardiol Clin 2018; 36:221-223. http://www.ncbi.nlm.nih.gov/pubmed/?term=29609751
  3. McKeand W, Baird-Bellaire S, Ermer J, Patat A. A Study of the Potential Interaction Between Bazedoxifene and Atorvastatin in Healthy Postmenopausal Women. Clinical pharmacology in drug development 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29683561
  4. Oh GC, Han JK, Han KH et al. Efficacy and Safety of Fixed-dose Combination Therapy With Telmisartan and Rosuvastatin in Korean Patients With Hypertension and Dyslipidemia: TELSTA-YU (TELmisartan-rosuvaSTAtin from YUhan), a Multicenter, Randomized, 4-Arm, Double-blind, Placebo-controlled, Phase III Study. Clinical therapeutics 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29673890
  5. Kim H, Choi HY, Kim YH et al. Pharmacokinetic interactions and tolerability of rosuvastatin and ezetimibe: an open-label, randomized, multiple-dose, crossover study in healthy male volunteers. Drug design, development and therapy 2018; 12:815-821. http://www.ncbi.nlm.nih.gov/pubmed/?term=29692602
  6. Lee J, Rhee SJ, Lee S, Yu KS. Evaluation of drug interactions between fimasartan and rosuvastatin after single and multiple doses in healthy Caucasians. Drug design, development and therapy 2018; 12:787-794. http://www.ncbi.nlm.nih.gov/pubmed/?term=29670335
  7. Schol-Gelok S, van der Hulle T, Biedermann JS et al. Clinical effects of antiplatelet drugs and statins on D-dimer levels. European journal of clinical investigation 2018:e12944. http://www.ncbi.nlm.nih.gov/pubmed/?term=29682728
  8. Singh K, Crossan C, Laba TL et al. Cost-effectiveness of a fixed dose combination (polypill) in secondary prevention of cardiovascular diseases in India: Within-trial cost-effectiveness analysis of the UMPIRE trial. Int J Cardiol 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29622506
  9. Farrag SM, Hamzawy MA, El-Yamany MF et al. Atorvastatin in nano-particulate formulation abates muscle and liver affliction when coalesced with coenzyme Q10 and/or vitamin E in hyperlipidemic rats. Life sciences 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29694831
  10. Patel SS, Guzman L, Lin FP et al. Utilization of Aspirin and Statin in Management of Coronary Artery Disease in Patients with Cirrhosis Undergoing Liver Transplant Evaluation. Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29624871
  11. Lin SH, Cheng PC, Tu ST et al. Effect of metformin monotherapy on serum lipid profile in statin-naive individuals with newly diagnosed type 2 diabetes mellitus: a cohort study. PeerJ 2018; 6:e4578. http://www.ncbi.nlm.nih.gov/pubmed/?term=29666753
  12. Bech AP, Wetzels JFM, Nijenhuis T. Effects of sildenafil, metformin, and simvastatin on ADH-independent urine concentration in healthy volunteers. Physiological reports 2018; 6:e13665. http://www.ncbi.nlm.nih.gov/pubmed/?term=29611351
  13. Matsubara A, Oda S, Akai S et al. Establishment of a drug-induced rhabdomyolysis mouse model by co-administration of ciprofloxacin and atorvastatin. Toxicology letters 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29679711

Adherence

  1. Wu Z, Camargo CA, Jr., Khaw KT et al. Effects of vitamin D supplementation on adherence to and persistence with long-term statin therapy: Secondary analysis from the randomized, double-blind, placebo-controlled ViDA study. Atherosclerosis 2018; 273:59-66. http://www.ncbi.nlm.nih.gov/pubmed/?term=29684661
  2. Kruger K, Leppkes N, Gehrke-Beck S et al. Improving long-term adherence to statin therapy: a qualitative study of GPs' experiences in primary care. Br J Gen Pract 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29686133
  3. Banach M, Mikhailidis DP. Statin Intolerance: Some Practical Hints. Cardiol Clin 2018; 36:225-231. http://www.ncbi.nlm.nih.gov/pubmed/?term=29609752
  4. Andelius L, Mortensen MB, Norgaard BL, Abdulla J. Impact of statin therapy on coronary plaque burden and composition assessed by coronary computed tomographic angiography: a systematic review and meta-analysis. European heart journal cardiovascular Imaging 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29617981
  5. Haddad C, Hallit S, Salhab M et al. Association Between Adherence to Statins, Illness Perception, Treatment Satisfaction, and Quality of Life among Lebanese patients. Journal of cardiovascular pharmacology and therapeutics 2018:1074248418769635. http://www.ncbi.nlm.nih.gov/pubmed/?term=29683005
  6. Ofori-Asenso R, Llomaki J, Tacey M et al. Patterns of Statin Use and Long-term Adherence and Persistence among Older Adults with Diabetes. Journal of diabetes 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29658177

Atherosclerosis & Imaging

  1. Berwanger O, de Barros ESPGM, Dall Orto FTC et al. Rationale and design of the Statins Evaluation in Coronary procedUres and REvascularization: The SECURE-PCI Trial. Am Heart J 2018; 198:129-134. http://www.ncbi.nlm.nih.gov/pubmed/?term=29653634
  2. Muniyappa R, Noureldin RA, Abd-Elmoniem KZ et al. Personalized Statin Therapy and Coronary Atherosclerotic Plaque Burden in Asymptomatic Low/Intermediate-Risk Individuals. Cardiorenal Med 2018; 8:140-150. http://www.ncbi.nlm.nih.gov/pubmed/?term=29617001
  3. Masaki N, Kumagai K, Sasaki K et al. Suppressive effect of pitavastatin on aortic arch dilatation in acute stanford type B aortic dissection: analysis of STANP trial. General thoracic and cardiovascular surgery 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29626287
  4. Yamashita M, Iwata A, Kato Y et al. Impact of the triglyceride level on coronary plaque components in female patients with coronary artery disease treated with statins. Heart Vessels 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29696358
  5. Ako J, Hibi K, Kozuma K et al. Effect of alirocumab on coronary atheroma volume in Japanese patients with acute coronary syndromes and hypercholesterolemia not adequately controlled with statins: ODYSSEY J-IVUS rationale and design. J Cardiol 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29606415
  6. Bekki M, Tahara N, Tahara A et al. Anti-inflammatory effect of statin in coronary aneurysms late after Kawasaki disease. Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29667011
  7. Takata K, Kataoka Y, Andrews J et al. Triglyceride-to-High-Density Lipoprotein Cholesterol Ratio and Vulnerable Plaque Features With Statin Therapy in Diabetic Patients With Coronary Artery Disease: Frequency-Domain Optical Coherence Tomography Analysis. JACC. Cardiovascular imaging 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29680344
  8. Kato Y, Iwata A, Futami M et al. Impact of von Willebrand factor on coronary plaque burden in coronary artery disease patients treated with statins. Medicine (Baltimore) 2018; 97:e0589. http://www.ncbi.nlm.nih.gov/pubmed/?term=29703054

Atorvastatin/Rosuvastatin

  1. Shahid N, Adnan S, Farooq M et al. Development of compressed coated polypill with mucoadhesive core comprising of atorvastatin/clopidogrel/aspirin using compression coating technique. Acta poloniae pharmaceutica 2017; 74:477-487. http://www.ncbi.nlm.nih.gov/pubmed/?term=29624252
  2. Berwanger O, de Barros ESPGM, Dall Orto FTC et al. Rationale and design of the Statins Evaluation in Coronary procedUres and REvascularization: The SECURE-PCI Trial. Am Heart J 2018; 198:129-134. http://www.ncbi.nlm.nih.gov/pubmed/?term=29653634
  3. Chiorescu S, Grad NO, Mironiuc IA, Andercou OA. Rosuvastatin administered intraperitoneally reduces the formation of postoperative adhesions in rats. Annali italiani di chirurgia 2018; 89:95-100. http://www.ncbi.nlm.nih.gov/pubmed/?term=29629882
  4. Shahsavari G, Raoufi A, Toolabi A et al. The effect of atorvastatin treatment duration on oxidative stress markers and lipid profile in patients with coronary artery diseases: A case series study. ARYA atherosclerosis 2017; 13:282-287. http://www.ncbi.nlm.nih.gov/pubmed/?term=29643923
  5. Pontes HBD, Pontes J, Azevedo Neto E et al. Evaluation of the Effects of Atorvastatin and Ischemic Postconditioning Preventing on the Ischemia and Reperfusion Injury: Experimental Study in Rats. Brazilian journal of cardiovascular surgery 2018; 33:72-81. http://www.ncbi.nlm.nih.gov/pubmed/?term=29617505
  6. Chen Y, Chang Y, Zhang N et al. Atorvastatin Attenuates Myocardial Hypertrophy in Spontaneously Hypertensive Rats via the C/EBPbeta/PGC-1alpha/UCP3 Pathway. Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology 2018; 46:1009-1018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29669326
  7. Docrat TF, Nagiah S, Krishnan A et al. Atorvastatin induces MicroRNA-145 expression in HEPG2 cells via regulation of the PI3K/AKT signalling pathway. Chemico-biological interactions 2018; 287:32-40. http://www.ncbi.nlm.nih.gov/pubmed/?term=29630879
  8. Bodde MC, Welsh P, Bergheanu SC et al. A rapid (differential) effect of rosuvastatin and atorvastatin on high-sensitivity cardiac Troponin-I in subjects with stable cardiovascular disease. Clinical pharmacology and therapeutics 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29672821
  9. Garcia-Guzman P, Medina-Torres L, Calderas F et al. Characterization of hybrid microparticles/Montmorillonite composite with raspberry-like morphology for Atorvastatin controlled release. Colloids and surfaces. B, Biointerfaces 2018; 167:397-406. http://www.ncbi.nlm.nih.gov/pubmed/?term=29702471
  10. Lee J, Rhee SJ, Lee S, Yu KS. Evaluation of drug interactions between fimasartan and rosuvastatin after single and multiple doses in healthy Caucasians. Drug design, development and therapy 2018; 12:787-794. http://www.ncbi.nlm.nih.gov/pubmed/?term=29670335
  11. Liu Y, Song X, Zhou H et al. Gut Microbiome Associates With Lipid-Lowering Effect of Rosuvastatin in Vivo. Frontiers in microbiology 2018; 9:530. http://www.ncbi.nlm.nih.gov/pubmed/?term=29623075
  12. Hua S, Ma C, Zhang J et al. Influence of APOA5 Locus on the Treatment Efficacy of Three Statins: Evidence From a Randomized Pilot Study in Chinese Subjects. Frontiers in pharmacology 2018; 9:352. http://www.ncbi.nlm.nih.gov/pubmed/?term=29695967
  13. Ahmadi Y, Haghjoo AG, Dastmalchi S et al. Effects of Rosuvastatin on the expression of the genes involved in cholesterol metabolism in rat: Adaptive responses by extrahepatic tissues. Gene 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29605604
  14. Kaasenbrood L, Ray KK, Boekholdt SM et al. Estimated individual lifetime benefit from PCSK9 inhibition in statin-treated patients with coronary artery disease. Heart 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29622600
  15. Bimbova K, Bacova M, Kisucka A et al. A Single Dose of Atorvastatin Applied Acutely after Spinal Cord Injury Suppresses Inflammation, Apoptosis, and Promotes Axon Outgrowth, Which Might Be Essential for Favorable Functional Outcome. Int J Mol Sci 2018; 19. http://www.ncbi.nlm.nih.gov/pubmed/?term=29642434
  16. Peters SAE, Colantonio LD, Zhao H et al. Sex Differences in High-Intensity Statin Use Following Myocardial Infarction in the United States. J Am Coll Cardiol 2018; 71:1729-1737. http://www.ncbi.nlm.nih.gov/pubmed/?term=29673463
  17. Volgman AS, Dembowski E, Braun LT. Should Sex Matter When it Comes to High-Intensity Statins? J Am Coll Cardiol 2018; 71:1738-1740. http://www.ncbi.nlm.nih.gov/pubmed/?term=29673464
  18. Zeng X, Su W, Liu H et al. Simultaneous determination of rosuvastatin, naringin and naringenin in rat plasma by RRLC-MS/MS and its application to a pharmacokinetic drug interaction study. Journal of chromatographic science 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29701749
  19. Nguyen S, Chuah SY, Fontas E et al. Atorvastatin in Combination With Narrowband UV-B in Adult Patients With Active Vitiligo: A Randomized Clinical Trial. JAMA dermatology 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29617528
  20. Farrag SM, Hamzawy MA, El-Yamany MF et al. Atorvastatin in nano-particulate formulation abates muscle and liver affliction when coalesced with coenzyme Q10 and/or vitamin E in hyperlipidemic rats. Life sciences 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29694831
  21. Lee CH, Hsieh MJ, Liu SC et al. Novel bifurcation stents coated with bioabsorbable nanofibers with extended and controlled release of rosuvastatin and paclitaxel. Materials science & engineering. C, Materials for biological applications 2018; 88:61-69. http://www.ncbi.nlm.nih.gov/pubmed/?term=29636139
  22. Wang K, Chen L, Liu L et al. The effects of atorvastatin on IL-6, CRP, blood lipid and myocardial protection of interventional therapy in patients with acute myocardial infarction. Minerva medica 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29696937
  23. Rocha B, Rodrigues AR, Tomada I et al. Energy restriction, exercise and atorvastatin treatment improve endothelial dysfunction and inhibit miRNA-155 in the erectile tissue of the aged rat. Nutrition & metabolism 2018; 15:28. http://www.ncbi.nlm.nih.gov/pubmed/?term=29686722
  24. Miranda HF, Sierralta F, Aranda N et al. Antinociception induced by rosuvastatin in murine neuropathic pain. Pharmacological reports : PR 2017; 70:503-508. http://www.ncbi.nlm.nih.gov/pubmed/?term=29660653
  25. Lettiero B, Inasu M, Kimbung S, Borgquist S. Insensitivity to atorvastatin is associated with increased accumulation of intracellular lipid droplets and fatty acid metabolism in breast cancer cells. Scientific reports 2018; 8:5462. http://www.ncbi.nlm.nih.gov/pubmed/?term=29615666
  26. Lim YI, Han J, Woo YA et al. Rapid quantitation of atorvastatin in process pharmaceutical powder sample using Raman spectroscopy and evaluation of parameters related to accuracy of analysis. Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy 2018; 200:26-32. http://www.ncbi.nlm.nih.gov/pubmed/?term=29660679
  27. Matsubara A, Oda S, Akai S et al. Establishment of a drug-induced rhabdomyolysis mouse model by co-administration of ciprofloxacin and atorvastatin. Toxicology letters 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29679711

Basic science

  1. Gu F, Ning J, Fan H et al. Preparation and characterization of simvastatin/DMbetaCD complex and its pharmacokinetics in rats. Acta pharmaceutica (Zagreb, Croatia) 2018; 68:145-157. http://www.ncbi.nlm.nih.gov/pubmed/?term=29702479
  2. Shahid N, Adnan S, Farooq M et al. Development of compressed coated polypill with mucoadhesive core comprising of atorvastatin/clopidogrel/aspirin using compression coating technique. Acta poloniae pharmaceutica 2017; 74:477-487. http://www.ncbi.nlm.nih.gov/pubmed/?term=29624252
  3. Chiorescu S, Grad NO, Mironiuc IA, Andercou OA. Rosuvastatin administered intraperitoneally reduces the formation of postoperative adhesions in rats. Annali italiani di chirurgia 2018; 89:95-100. http://www.ncbi.nlm.nih.gov/pubmed/?term=29629882
  4. Zhou Y, Yang H, Zhou X et al. Lovastatin synergizes with itraconazole against planktonic cells and biofilms of Candida albicans through the regulation on ergosterol biosynthesis pathway. Applied microbiology and biotechnology 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29691631
  5. Thabit S, El Sayed NSE. Effect of pioglitazone and simvastatin in lipopolysaccharide-induced amyloidogenesis and cognitive impairment in mice: possible role of glutamatergic pathway and oxidative stress. Behavioural pharmacology 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29659380
  6. Liu Y, Feng Y, Cheng D et al. Dynamics of bacterial composition and the fate of antibiotic resistance genes and mobile genetic elements during the co-composting with gentamicin fermentation residue and lovastatin fermentation residue. Bioresource technology 2018; 261:249-256. http://www.ncbi.nlm.nih.gov/pubmed/?term=29673993
  7. Liang B, Huang X, Teng Y et al. Enhanced single-step bioproduction of the simvastatin precursor monacolin J in an industrial strain of Aspergillus terreus by employing the evolved lovastatin hydrolase. Biotechnology journal 2018:e1800094. http://www.ncbi.nlm.nih.gov/pubmed/?term=29637704
  8. Pontes HBD, Pontes J, Azevedo Neto E et al. Evaluation of the Effects of Atorvastatin and Ischemic Postconditioning Preventing on the Ischemia and Reperfusion Injury: Experimental Study in Rats. Brazilian journal of cardiovascular surgery 2018; 33:72-81. http://www.ncbi.nlm.nih.gov/pubmed/?term=29617505
  9. Yin Y, Liu L, Zhao Z et al. Simvastatin inhibits sonic hedgehog signaling and stemness features of pancreatic cancer. Cancer letters 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29627496
  10. Wang N, Lu Y, Wang K et al. Simvastatin Attenuates Neurogenetic Damage and Improves Neurocongnitive Deficits Induced by Isoflurane in Neonatal Rats. Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology 2018; 46:618-632. http://www.ncbi.nlm.nih.gov/pubmed/?term=29617679
  11. Docrat TF, Nagiah S, Krishnan A et al. Atorvastatin induces MicroRNA-145 expression in HEPG2 cells via regulation of the PI3K/AKT signalling pathway. Chemico-biological interactions 2018; 287:32-40. http://www.ncbi.nlm.nih.gov/pubmed/?term=29630879
  12. Zhang GQ, Tao YK, Bai YP et al. Inhibitory Effects of Simvastatin on Oxidized Low-Density Lipoprotein-Induced Endoplasmic Reticulum Stress and Apoptosis in Vascular Endothelial Cells. Chinese medical journal 2018; 131:950-955. http://www.ncbi.nlm.nih.gov/pubmed/?term=29664056
  13. Ames PRJ, Di Girolamo G, D'Andrea G et al. Predictive Value of Oxidized Low-Density Lipoprotein/beta2-Glycoprotein-I Complexes (oxLDL/beta2GPI) in Nonautoimmune Atherothrombosis. Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis 2018:1076029618767752. http://www.ncbi.nlm.nih.gov/pubmed/?term=29669439
  14. Garcia-Guzman P, Medina-Torres L, Calderas F et al. Characterization of hybrid microparticles/Montmorillonite composite with raspberry-like morphology for Atorvastatin controlled release. Colloids and surfaces. B, Biointerfaces 2018; 167:397-406. http://www.ncbi.nlm.nih.gov/pubmed/?term=29702471
  15. Liao Y, Zhang P, Yuan B et al. Pravastatin Protects Against Avascular Necrosis of Femoral Head via Autophagy. Front Physiol 2018; 9:307. http://www.ncbi.nlm.nih.gov/pubmed/?term=29686621
  16. Ahmadi Y, Haghjoo AG, Dastmalchi S et al. Effects of Rosuvastatin on the expression of the genes involved in cholesterol metabolism in rat: Adaptive responses by extrahepatic tissues. Gene 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29605604
  17. Bimbova K, Bacova M, Kisucka A et al. A Single Dose of Atorvastatin Applied Acutely after Spinal Cord Injury Suppresses Inflammation, Apoptosis, and Promotes Axon Outgrowth, Which Might Be Essential for Favorable Functional Outcome. Int J Mol Sci 2018; 19. http://www.ncbi.nlm.nih.gov/pubmed/?term=29642434
  18. Viczenczova C, Kura B, Egan Benova T et al. Irradiation-Induced Cardiac Connexin-43 and miR-21 Responses Are Hampered by Treatment with Atorvastatin and Aspirin. Int J Mol Sci 2018; 19. http://www.ncbi.nlm.nih.gov/pubmed/?term=29642568
  19. Zeng X, Su W, Liu H et al. Simultaneous determination of rosuvastatin, naringin and naringenin in rat plasma by RRLC-MS/MS and its application to a pharmacokinetic drug interaction study. Journal of chromatographic science 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29701749
  20. Min JJ, Shin BS, Lee JH et al. Effects of Pravastatin on Type 1 Diabetic Rat Heart with or without Blood Glycemic Control. Journal of diabetes research 2018; 2018:1067853. http://www.ncbi.nlm.nih.gov/pubmed/?term=29682576
  21. Soares DG, Anovazzi G, Bordini EAF et al. Biological Analysis of Simvastatin-releasing Chitosan Scaffold as a Cell-free System for Pulp-dentin Regeneration. Journal of endodontics 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29703618
  22. Yoon SJ, Kim EC, Noh K, Lee DW. Supramolecular Hydrogels Based on MPEG-Grafted Hyaluronic Acid and alpha-CD Containing HP-beta-CD/Simvastatin Enhance Osteogenesis In Vivo. Journal of nanoscience and nanotechnology 2017; 17:217-223. http://www.ncbi.nlm.nih.gov/pubmed/?term=29617547
  23. Clementino A, Sonvico F. Development and validation of a RP-HPLC method for the simultaneous detection and quantification of simvastatin's isoforms and coenzyme Q10 in lecithin/chitosan nanoparticles. Journal of pharmaceutical and biomedical analysis 2018; 155:33-41. http://www.ncbi.nlm.nih.gov/pubmed/?term=29605683
  24. Lee Y, Pai SB, Bellamkonda RV et al. Cerivastatin Nano-Liposome as a Potential Disease Modifying Approach for the Treatment of Pulmonary Arterial Hypertension. J Pharmacol Exp Ther 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29695410
  25. Garrett N, Pombo J, Umpierrez M et al. Pravastatin therapy during preeclampsia prevents long-term adverse health effects in mice. JCI insight 2018; 3. http://www.ncbi.nlm.nih.gov/pubmed/?term=29669946
  26. Farrag SM, Hamzawy MA, El-Yamany MF et al. Atorvastatin in nano-particulate formulation abates muscle and liver affliction when coalesced with coenzyme Q10 and/or vitamin E in hyperlipidemic rats. Life sciences 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29694831
  27. Lee CH, Hsieh MJ, Liu SC et al. Novel bifurcation stents coated with bioabsorbable nanofibers with extended and controlled release of rosuvastatin and paclitaxel. Materials science & engineering. C, Materials for biological applications 2018; 88:61-69. http://www.ncbi.nlm.nih.gov/pubmed/?term=29636139
  28. Ekerbicer N, Gurpinar T, Sisman AR et al. Statins reduce testicular and ocular VEGF: A potential compromise to microcirculation. Microvascular research 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29678729
  29. Rocha B, Rodrigues AR, Tomada I et al. Energy restriction, exercise and atorvastatin treatment improve endothelial dysfunction and inhibit miRNA-155 in the erectile tissue of the aged rat. Nutrition & metabolism 2018; 15:28. http://www.ncbi.nlm.nih.gov/pubmed/?term=29686722
  30. Miranda HF, Sierralta F, Aranda N et al. Antinociception induced by rosuvastatin in murine neuropathic pain. Pharmacological reports : PR 2017; 70:503-508. http://www.ncbi.nlm.nih.gov/pubmed/?term=29660653
  31. Cruz P, Reyes F, Torres CG. Simvastatin modulates beta-catenin/MDR1 expression on spheres derived from CF41.Mg canine mammary carcinoma cells. Polish journal of veterinary sciences 2018; 21:95-99. http://www.ncbi.nlm.nih.gov/pubmed/?term=29624022
  32. Snarska A, Gonkowski S, Rytel L et al. Influence of simvastatin on red blood cell line in porcine bone marrow. Polish journal of veterinary sciences 2017; 20:811-814. http://www.ncbi.nlm.nih.gov/pubmed/?term=29611640
  33. Lim YI, Han J, Woo YA et al. Rapid quantitation of atorvastatin in process pharmaceutical powder sample using Raman spectroscopy and evaluation of parameters related to accuracy of analysis. Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy 2018; 200:26-32. http://www.ncbi.nlm.nih.gov/pubmed/?term=29660679
  34. Matsubara A, Oda S, Akai S et al. Establishment of a drug-induced rhabdomyolysis mouse model by co-administration of ciprofloxacin and atorvastatin. Toxicology letters 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29679711
  35. Huai J, Yang Z, Yi YH et al. [Regulation of pravastatin on long-chain fatty acid oxidative enzyme in pre-eclampsia-like mouse model]. Zhonghua fu chan ke za zhi 2018; 53:183-189. http://www.ncbi.nlm.nih.gov/pubmed/?term=29609233

Cancer

  1. Yin Y, Liu L, Zhao Z et al. Simvastatin inhibits sonic hedgehog signaling and stemness features of pancreatic cancer. Cancer letters 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29627496
  2. Desai P, Wallace R, Anderson ML et al. An analysis of the effect of statins on the risk of Non-Hodgkin's Lymphoma in the Women's Health Initiative cohort. Cancer medicine 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29608241
  3. Fowke JH, Motley SS. Statin Use Linked with a Decrease in the Conversion from High-Grade Prostatic Intraepithelial Neoplasia (HGPIN) to Prostate Cancer. Carcinogenesis 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29617729
  4. Chen YA, Lin YJ, Lin CL et al. Simvastatin Therapy for Drug Repositioning to Reduce the Risk of Prostate Cancer Mortality in Patients With Hyperlipidemia. Frontiers in pharmacology 2018; 9:225. http://www.ncbi.nlm.nih.gov/pubmed/?term=29623039
  5. Viczenczova C, Kura B, Egan Benova T et al. Irradiation-Induced Cardiac Connexin-43 and miR-21 Responses Are Hampered by Treatment with Atorvastatin and Aspirin. Int J Mol Sci 2018; 19. http://www.ncbi.nlm.nih.gov/pubmed/?term=29642568
  6. Tsakiridou ED, Liberopoulos E, Giotaki Z, Tigas S. Proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitor use in the management of resistant hypercholesterolemia induced by mitotane treatment for adrenocortical cancer. J Clin Lipidol 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29650402
  7. Lettiero B, Inasu M, Kimbung S, Borgquist S. Insensitivity to atorvastatin is associated with increased accumulation of intracellular lipid droplets and fatty acid metabolism in breast cancer cells. Scientific reports 2018; 8:5462. http://www.ncbi.nlm.nih.gov/pubmed/?term=29615666
  8. Wang JJ, Tian Y, Xu KL et al. [Statins Regulate the Proliferation and Apoptosis of T-ALL Cells through the Inhibition of Akt Pathway]. Zhongguo shi yan xue ye xue za zhi 2018; 26:359-367. http://www.ncbi.nlm.nih.gov/pubmed/?term=29665899

Children

  1. Harlow KE, Africa JA, Wells A et al. Clinically Actionable Hypercholesterolemia and Hypertriglyceridemia in Children with Nonalcoholic Fatty Liver Disease. J Pediatr 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29661561

Cost-effectiveness

  1. Jarmul J, Pletcher MJ, Hassmiller Lich K et al. Cardiovascular Genetic Risk Testing for Targeting Statin Therapy in the Primary Prevention of Atherosclerotic Cardiovascular Disease: A Cost-Effectiveness Analysis. Circ Cardiovasc Qual Outcomes 2018; 11:e004171. http://www.ncbi.nlm.nih.gov/pubmed/?term=29650716
  2. Lee TC, Kaouache M, Grover SA. Evaluation of the cost-effectiveness of evolocumab in the FOURIER study: a Canadian analysis. CMAJ open 2018; 6:E162-e167. http://www.ncbi.nlm.nih.gov/pubmed/?term=29622685
  3. Singh K, Crossan C, Laba TL et al. Cost-effectiveness of a fixed dose combination (polypill) in secondary prevention of cardiovascular diseases in India: Within-trial cost-effectiveness analysis of the UMPIRE trial. Int J Cardiol 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29622506
  4. Mitchell D, Guertin JR, Dubois A et al. A Discrete Event Simulation Model to Assess the Economic Value of a Hypothetical Pharmacogenomics Test for Statin-Induced Myopathy in Patients Initiating a Statin in Secondary Cardiovascular Prevention. Molecular diagnosis & therapy 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29651791

CVD

  1. Shahsavari G, Raoufi A, Toolabi A et al. The effect of atorvastatin treatment duration on oxidative stress markers and lipid profile in patients with coronary artery diseases: A case series study. ARYA atherosclerosis 2017; 13:282-287. http://www.ncbi.nlm.nih.gov/pubmed/?term=29643923
  2. Rozenbaum Z, Ravid D, Margolis G et al. Association of Pre-Admission Statin Therapy and the Inflammatory Response in ST Elevation Myocardial Infarction patients. Biomarkers 2018:1-19. http://www.ncbi.nlm.nih.gov/pubmed/?term=29620476
  3. Vallejo-Vaz AJ, Fayyad R, Boekholdt SM et al. Triglyceride-Rich Lipoprotein Cholesterol and Risk of Cardiovascular Events Among Patients Receiving Statin Therapy in the Treating to New Targets (TNT) Trial. Circulation 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29618599
  4. Bodde MC, Welsh P, Bergheanu SC et al. A rapid (differential) effect of rosuvastatin and atorvastatin on high-sensitivity cardiac Troponin-I in subjects with stable cardiovascular disease. Clinical pharmacology and therapeutics 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29672821
  5. Kaasenbrood L, Ray KK, Boekholdt SM et al. Estimated individual lifetime benefit from PCSK9 inhibition in statin-treated patients with coronary artery disease. Heart 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29622600
  6. Singh K, Crossan C, Laba TL et al. Cost-effectiveness of a fixed dose combination (polypill) in secondary prevention of cardiovascular diseases in India: Within-trial cost-effectiveness analysis of the UMPIRE trial. Int J Cardiol 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29622506
  7. Peters SAE, Colantonio LD, Zhao H et al. Sex Differences in High-Intensity Statin Use Following Myocardial Infarction in the United States. J Am Coll Cardiol 2018; 71:1729-1737. http://www.ncbi.nlm.nih.gov/pubmed/?term=29673463
  8. Volgman AS, Dembowski E, Braun LT. Should Sex Matter When it Comes to High-Intensity Statins? J Am Coll Cardiol 2018; 71:1738-1740. http://www.ncbi.nlm.nih.gov/pubmed/?term=29673464
  9. Ham SY, Song SW, Nam SB et al. Effects of chronic statin use on 30-day major adverse cardiac and cerebrovascular events after thoracic endovascular aortic repair. J Cardiovasc Surg (Torino) 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29616526
  10. Anderson JL, Knowlton KU, May HT et al. Temporal changes in statin prescription and intensity at discharge and impact on outcomes in patients with newly diagnosed atherosclerotic cardiovascular disease-Real-world experience within a large integrated health care system: The IMPRES study. J Clin Lipidol 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29703626
  11. Yamac AH, Kilic U. Effect of statins on sirtuin 1 and endothelial nitric oxide synthase expression in young patients with a history of premature myocardial infarction. Turk Kardiyoloji Dernegi arsivi : Turk Kardiyoloji Derneginin yayin organidir 2018; 46:205-215. http://www.ncbi.nlm.nih.gov/pubmed/?term=29664427

Endothelium/inflammation

  1. Shahsavari G, Raoufi A, Toolabi A et al. The effect of atorvastatin treatment duration on oxidative stress markers and lipid profile in patients with coronary artery diseases: A case series study. ARYA atherosclerosis 2017; 13:282-287. http://www.ncbi.nlm.nih.gov/pubmed/?term=29643923
  2. Rozenbaum Z, Ravid D, Margolis G et al. Association of Pre-Admission Statin Therapy and the Inflammatory Response in ST Elevation Myocardial Infarction patients. Biomarkers 2018:1-19. http://www.ncbi.nlm.nih.gov/pubmed/?term=29620476
  3. Munkhaugen J, Otterstad JE, Dammen T et al. The prevalence and predictors of elevated C-reactive protein after a coronary heart disease event. Eur J Prev Cardiol 2018:2047487318768940. http://www.ncbi.nlm.nih.gov/pubmed/?term=29635941
  4. Bekki M, Tahara N, Tahara A et al. Anti-inflammatory effect of statin in coronary aneurysms late after Kawasaki disease. Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29667011
  5. Wang K, Chen L, Liu L et al. The effects of atorvastatin on IL-6, CRP, blood lipid and myocardial protection of interventional therapy in patients with acute myocardial infarction. Minerva medica 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29696937

Ethnicity

  1. Naganuma T, Tsujita K, Mitomo S et al. Impact of Chronic Kidney Disease on Outcomes After Percutaneous Coronary Intervention for Chronic Total Occlusions (from the Japanese Multicenter Registry). Am J Cardiol 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29627112
  2. Umeda T, Hayashi A, Harada A et al. Low-Density Lipoprotein Cholesterol Goal Attainment Rates by Initial Statin Monotherapy Among Patients With Dyslipidemia and High Cardiovascular Risk in Japan- A Retrospective Database Analysis. Circulation journal : official journal of the Japanese Circulation Society 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29628458
  3. Oh GC, Han JK, Han KH et al. Efficacy and Safety of Fixed-dose Combination Therapy With Telmisartan and Rosuvastatin in Korean Patients With Hypertension and Dyslipidemia: TELSTA-YU (TELmisartan-rosuvaSTAtin from YUhan), a Multicenter, Randomized, 4-Arm, Double-blind, Placebo-controlled, Phase III Study. Clinical therapeutics 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29673890
  4. Itoh H, Komuro I, Takeuchi M et al. Intensive Treat-to-Target Statin Therapy in High-Risk Japanese Patients With Hypercholesterolemia and Diabetic Retinopathy: Report of a Randomized Study. Diabetes Care 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29626074
  5. Hua S, Ma C, Zhang J et al. Influence of APOA5 Locus on the Treatment Efficacy of Three Statins: Evidence From a Randomized Pilot Study in Chinese Subjects. Frontiers in pharmacology 2018; 9:352. http://www.ncbi.nlm.nih.gov/pubmed/?term=29695967
  6. Hashiguchi M, Hakamata J, Shimizu M et al. Risk factors for rhabdomyolysis with HMG-CoA reductase inhibitors identified using a postmarketing surveillance database in Japan. International journal of clinical pharmacology and therapeutics 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29701171
  7. Wang K, Chen L, Liu L et al. The effects of atorvastatin on IL-6, CRP, blood lipid and myocardial protection of interventional therapy in patients with acute myocardial infarction. Minerva medica 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29696937
  8. Sadeeqa S, Maqsood M, Ahmad M. Prevalence of statin induced myopathy in Lahore, Pakistan. Pak J Pharm Sci 2018; 31:617-622. http://www.ncbi.nlm.nih.gov/pubmed/?term=29625933
  9. Lee SE, Sung JM, Cho IJ et al. Risk of new-onset diabetes among patients treated with statins according to hypertension and gender: Results from a nationwide health-screening cohort. PLoS One 2018; 13:e0195459. http://www.ncbi.nlm.nih.gov/pubmed/?term=29630642
  10. Momo K, Takagi A, Miyaji A, Koinuma M. Assessment of statin-induced interstitial pneumonia in patients treated for hyperlipidemia using a health insurance claims database in Japan. Pulmonary pharmacology & therapeutics 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29627482

FH

  1. Zenti MG, Stefanutti C, Sanga V et al. Evolocumab and lipoprotein apheresis combination therapy may have synergic effects to reduce low-density lipoprotein cholesterol levels in heterozygous familial hypercholesterolemia: A case report. Journal of clinical apheresis 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29638018
  2. Ridker PM, Rose LM, Kastelein JJP et al. Cardiovascular event reduction with PCSK9 inhibition among 1578 patients with familial hypercholesterolemia: Results from the SPIRE randomized trials of bococizumab. J Clin Lipidol 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29685591
  3. Pang J, Martin AC, Bates TR et al. Parent-child genetic testing for familial hypercholesterolaemia in an Australian context. Journal of paediatrics and child health 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29626384

Genetics

  1. Jarmul J, Pletcher MJ, Hassmiller Lich K et al. Cardiovascular Genetic Risk Testing for Targeting Statin Therapy in the Primary Prevention of Atherosclerotic Cardiovascular Disease: A Cost-Effectiveness Analysis. Circ Cardiovasc Qual Outcomes 2018; 11:e004171. http://www.ncbi.nlm.nih.gov/pubmed/?term=29650716
  2. Wei WQ, Li X, Feng Q et al. LPA Variants are Associated with Residual Cardiovascular Risk in Patients Receiving Statins. Circulation 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29703846
  3. Hua S, Ma C, Zhang J et al. Influence of APOA5 Locus on the Treatment Efficacy of Three Statins: Evidence From a Randomized Pilot Study in Chinese Subjects. Frontiers in pharmacology 2018; 9:352. http://www.ncbi.nlm.nih.gov/pubmed/?term=29695967
  4. Ahmadi Y, Haghjoo AG, Dastmalchi S et al. Effects of Rosuvastatin on the expression of the genes involved in cholesterol metabolism in rat: Adaptive responses by extrahepatic tissues. Gene 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29605604
  5. Pang J, Martin AC, Bates TR et al. Parent-child genetic testing for familial hypercholesterolaemia in an Australian context. Journal of paediatrics and child health 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29626384
  6. Mitchell D, Guertin JR, Dubois A et al. A Discrete Event Simulation Model to Assess the Economic Value of a Hypothetical Pharmacogenomics Test for Statin-Induced Myopathy in Patients Initiating a Statin in Secondary Cardiovascular Prevention. Molecular diagnosis & therapy 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29651791

Guidelines

  1. Navar AM, Pencina MJ, Mulder H et al. Improving patient risk communication: Translating cardiovascular risk into standardized risk percentiles. Am Heart J 2018; 198:18-24. http://www.ncbi.nlm.nih.gov/pubmed/?term=29653642
  2. Cesena FHY, Laurinavicius AG, Valente VA et al. Statin Eligibility in Primary Prevention: From a Risk-Based Strategy to a Personalized Approach Based on the Predicted Benefit. Am J Cardiol 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29605080
  3. Bin Abdulhak AA, Robinson JG. Optimizing Statins and Ezetimibe in Guideline-Focused Management. Cardiol Clin 2018; 36:221-223. http://www.ncbi.nlm.nih.gov/pubmed/?term=29609751
  4. Masi S, Taddei S, Virdis A. Statin guidelines: Friend or foes?: Editorial for 'Validation of the 2016 USPSTF recommendations for primary cardiovascular prevention in a large contemporary cohort'. Eur J Prev Cardiol 2018:2047487318768941. http://www.ncbi.nlm.nih.gov/pubmed/?term=29629827
  5. Anderson JL, Knowlton KU, May HT et al. Temporal changes in statin prescription and intensity at discharge and impact on outcomes in patients with newly diagnosed atherosclerotic cardiovascular disease-Real-world experience within a large integrated health care system: The IMPRES study. J Clin Lipidol 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29703626
  6. DeJonckheere M, Robinson CH, Evans L et al. Designing for Clinical Change: Creating an Intervention to Implement New Statin Guidelines in a Primary Care Clinic. JMIR human factors 2018; 5:e19. http://www.ncbi.nlm.nih.gov/pubmed/?term=29691206
  7. Gant CM, Binnenmars SH, Harmelink M et al. Real-life achievement of lipid-lowering treatment targets in the DIAbetes and LifEstyle Cohort Twente: systemic assessment of pharmacological and nutritional factors. Nutrition & diabetes 2018; 8:24. http://www.ncbi.nlm.nih.gov/pubmed/?term=29695715
  8. Nutman A, Chodick G, Shalev V. The Potential Effects of Implementing the 2013 ACC/AHA Cholesterol Guidelines on the Use of Statins in a Large Health Maintenance Organization in Israel. Value in health regional issues 2015; 7:22-26. http://www.ncbi.nlm.nih.gov/pubmed/?term=29698148

LDL- related parameters

  1. Zhang GQ, Tao YK, Bai YP et al. Inhibitory Effects of Simvastatin on Oxidized Low-Density Lipoprotein-Induced Endoplasmic Reticulum Stress and Apoptosis in Vascular Endothelial Cells. Chinese medical journal 2018; 131:950-955. http://www.ncbi.nlm.nih.gov/pubmed/?term=29664056
  2. Umeda T, Hayashi A, Harada A et al. Low-Density Lipoprotein Cholesterol Goal Attainment Rates by Initial Statin Monotherapy Among Patients With Dyslipidemia and High Cardiovascular Risk in Japan- A Retrospective Database Analysis. Circulation journal : official journal of the Japanese Circulation Society 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29628458
  3. Ames PRJ, Di Girolamo G, D'Andrea G et al. Predictive Value of Oxidized Low-Density Lipoprotein/beta2-Glycoprotein-I Complexes (oxLDL/beta2GPI) in Nonautoimmune Atherothrombosis. Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis 2018:1076029618767752. http://www.ncbi.nlm.nih.gov/pubmed/?term=29669439
  4. Hua S, Ma C, Zhang J et al. Influence of APOA5 Locus on the Treatment Efficacy of Three Statins: Evidence From a Randomized Pilot Study in Chinese Subjects. Frontiers in pharmacology 2018; 9:352. http://www.ncbi.nlm.nih.gov/pubmed/?term=29695967
  5. Toth PP, Jones SR, Slee A et al. Relationship between lipoprotein subfraction cholesterol and residual risk for cardiovascular outcomes: A post hoc analysis of the AIM-HIGH trial. J Clin Lipidol 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29627296
  6. Shin D, Bohra C, Kongpakpaisarn K. Novel method versus the Friedewald method for estimating low-density lipoprotein cholesterol in determination of the eligibility for statin treatment for primary prevention in the United States. Medicine (Baltimore) 2018; 97:e0612. http://www.ncbi.nlm.nih.gov/pubmed/?term=29703063
  7. Welnicki M, Sliz D, Filipiak KJ et al. [Difference in efficacy of dyslipidaemia treatment in obese and not obese women. Analysis of date from 3ST-POL study]. Przeglad lekarski 2016; 73:353-358. http://www.ncbi.nlm.nih.gov/pubmed/?term=29668197

Lifestyle

  1. Gant CM, Binnenmars SH, Harmelink M et al. Real-life achievement of lipid-lowering treatment targets in the DIAbetes and LifEstyle Cohort Twente: systemic assessment of pharmacological and nutritional factors. Nutrition & diabetes 2018; 8:24. http://www.ncbi.nlm.nih.gov/pubmed/?term=29695715

Meta-analyses

  1. Andelius L, Mortensen MB, Norgaard BL, Abdulla J. Impact of statin therapy on coronary plaque burden and composition assessed by coronary computed tomographic angiography: a systematic review and meta-analysis. European heart journal cardiovascular Imaging 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29617981
  2. Zeng ZW, Zhang YN, Lin WX et al. A meta-analysis of pharmacological neuroprotection in noncardiac surgery: focus on statins, lidocaine, ketamine, and magnesium sulfate. Eur Rev Med Pharmacol Sci 2018; 22:1798-1811. http://www.ncbi.nlm.nih.gov/pubmed/?term=29630129

Metabolic Syndrome - Diabetes

  1. Nelson AJ, Nicholls SJ. Treating Dyslipidemia in Type 2 Diabetes. Cardiol Clin 2018; 36:233-239. http://www.ncbi.nlm.nih.gov/pubmed/?term=29609753
  2. Itoh H, Komuro I, Takeuchi M et al. Intensive Treat-to-Target Statin Therapy in High-Risk Japanese Patients With Hypercholesterolemia and Diabetic Retinopathy: Report of a Randomized Study. Diabetes Care 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29626074
  3. Ofori-Asenso R, Llomaki J, Tacey M et al. Patterns of Statin Use and Long-term Adherence and Persistence among Older Adults with Diabetes. Journal of diabetes 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29658177
  4. Min JJ, Shin BS, Lee JH et al. Effects of Pravastatin on Type 1 Diabetic Rat Heart with or without Blood Glycemic Control. Journal of diabetes research 2018; 2018:1067853. http://www.ncbi.nlm.nih.gov/pubmed/?term=29682576
  5. Takata K, Kataoka Y, Andrews J et al. Triglyceride-to-High-Density Lipoprotein Cholesterol Ratio and Vulnerable Plaque Features With Statin Therapy in Diabetic Patients With Coronary Artery Disease: Frequency-Domain Optical Coherence Tomography Analysis. JACC. Cardiovascular imaging 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29680344
  6. Gant CM, Binnenmars SH, Harmelink M et al. Real-life achievement of lipid-lowering treatment targets in the DIAbetes and LifEstyle Cohort Twente: systemic assessment of pharmacological and nutritional factors. Nutrition & diabetes 2018; 8:24. http://www.ncbi.nlm.nih.gov/pubmed/?term=29695715
  7. Iqbal K, Islam N, Azam I et al. Lack of association of statin use with vitamin D levels in a hospital based population of type 2 diabetes mellitus patients. Pak J Med Sci 2018; 34:204-208. http://www.ncbi.nlm.nih.gov/pubmed/?term=29643908
  8. Lin SH, Cheng PC, Tu ST et al. Effect of metformin monotherapy on serum lipid profile in statin-naive individuals with newly diagnosed type 2 diabetes mellitus: a cohort study. PeerJ 2018; 6:e4578. http://www.ncbi.nlm.nih.gov/pubmed/?term=29666753

New Treatments

  1. Patel RS, Scopelliti EM, Olugbile O. The Role of PCSK9 Inhibitors in the Treatment of Hypercholesterolemia. The Annals of pharmacotherapy 2018:1060028018771670. http://www.ncbi.nlm.nih.gov/pubmed/?term=29667842
  2. Barter PJ, Rye KA. Cholesteryl Ester Transfer Protein Inhibitors as Agents to Reduce Coronary Heart Disease Risk. Cardiol Clin 2018; 36:299-310. http://www.ncbi.nlm.nih.gov/pubmed/?term=29609759
  3. Saeed A, Ballantyne CM. Bempedoic Acid (ETC-1002): A Current Review. Cardiol Clin 2018; 36:257-264. http://www.ncbi.nlm.nih.gov/pubmed/?term=29609755
  4. Lee TC, Kaouache M, Grover SA. Evaluation of the cost-effectiveness of evolocumab in the FOURIER study: a Canadian analysis. CMAJ open 2018; 6:E162-e167. http://www.ncbi.nlm.nih.gov/pubmed/?term=29622685
  5. Kaasenbrood L, Ray KK, Boekholdt SM et al. Estimated individual lifetime benefit from PCSK9 inhibition in statin-treated patients with coronary artery disease. Heart 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29622600
  6. Ako J, Hibi K, Kozuma K et al. Effect of alirocumab on coronary atheroma volume in Japanese patients with acute coronary syndromes and hypercholesterolemia not adequately controlled with statins: ODYSSEY J-IVUS rationale and design. J Cardiol 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29606415
  7. Zenti MG, Stefanutti C, Sanga V et al. Evolocumab and lipoprotein apheresis combination therapy may have synergic effects to reduce low-density lipoprotein cholesterol levels in heterozygous familial hypercholesterolemia: A case report. Journal of clinical apheresis 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29638018
  8. Gauthier MS, Awan Z, Bouchard A et al. Posttranslational modification of proprotein convertase subtilisin/kexin type 9 is differentially regulated in response to distinct cardiometabolic treatments as revealed by targeted proteomics. J Clin Lipidol 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29699916
  9. Ridker PM, Rose LM, Kastelein JJP et al. Cardiovascular event reduction with PCSK9 inhibition among 1578 patients with familial hypercholesterolemia: Results from the SPIRE randomized trials of bococizumab. J Clin Lipidol 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29685591
  10. Tsakiridou ED, Liberopoulos E, Giotaki Z, Tigas S. Proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitor use in the management of resistant hypercholesterolemia induced by mitotane treatment for adrenocortical cancer. J Clin Lipidol 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29650402

PAD and statins

  1. Aday AW, Everett BM. Statins in Peripheral Artery Disease: What Are We Waiting For? Circulation 2018; 137:1447-1449. http://www.ncbi.nlm.nih.gov/pubmed/?term=29610126

Pleiotropic effects of statins

  1. Chiorescu S, Grad NO, Mironiuc IA, Andercou OA. Rosuvastatin administered intraperitoneally reduces the formation of postoperative adhesions in rats. Annali italiani di chirurgia 2018; 89:95-100. http://www.ncbi.nlm.nih.gov/pubmed/?term=29629882
  2. Rozenbaum Z, Ravid D, Margolis G et al. Association of Pre-Admission Statin Therapy and the Inflammatory Response in ST Elevation Myocardial Infarction patients. Biomarkers 2018:1-19. http://www.ncbi.nlm.nih.gov/pubmed/?term=29620476
  3. Pontes HBD, Pontes J, Azevedo Neto E et al. Evaluation of the Effects of Atorvastatin and Ischemic Postconditioning Preventing on the Ischemia and Reperfusion Injury: Experimental Study in Rats. Brazilian journal of cardiovascular surgery 2018; 33:72-81. http://www.ncbi.nlm.nih.gov/pubmed/?term=29617505
  4. Mermis JD, Simpson SQ. Statin Effect on Sepsis Mortality: Can We Close the Book? Chest 2018; 153:769-770. http://www.ncbi.nlm.nih.gov/pubmed/?term=29626965
  5. Bodde MC, Welsh P, Bergheanu SC et al. A rapid (differential) effect of rosuvastatin and atorvastatin on high-sensitivity cardiac Troponin-I in subjects with stable cardiovascular disease. Clinical pharmacology and therapeutics 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29672821
  6. Schol-Gelok S, van der Hulle T, Biedermann JS et al. Clinical effects of antiplatelet drugs and statins on D-dimer levels. European journal of clinical investigation 2018:e12944. http://www.ncbi.nlm.nih.gov/pubmed/?term=29682728
  7. Zeng ZW, Zhang YN, Lin WX et al. A meta-analysis of pharmacological neuroprotection in noncardiac surgery: focus on statins, lidocaine, ketamine, and magnesium sulfate. Eur Rev Med Pharmacol Sci 2018; 22:1798-1811. http://www.ncbi.nlm.nih.gov/pubmed/?term=29630129
  8. Liu Y, Song X, Zhou H et al. Gut Microbiome Associates With Lipid-Lowering Effect of Rosuvastatin in Vivo. Frontiers in microbiology 2018; 9:530. http://www.ncbi.nlm.nih.gov/pubmed/?term=29623075
  9. Chen YA, Lin YJ, Lin CL et al. Simvastatin Therapy for Drug Repositioning to Reduce the Risk of Prostate Cancer Mortality in Patients With Hyperlipidemia. Frontiers in pharmacology 2018; 9:225. http://www.ncbi.nlm.nih.gov/pubmed/?term=29623039
  10. Liao Y, Zhang P, Yuan B et al. Pravastatin Protects Against Avascular Necrosis of Femoral Head via Autophagy. Front Physiol 2018; 9:307. http://www.ncbi.nlm.nih.gov/pubmed/?term=29686621
  11. Bimbova K, Bacova M, Kisucka A et al. A Single Dose of Atorvastatin Applied Acutely after Spinal Cord Injury Suppresses Inflammation, Apoptosis, and Promotes Axon Outgrowth, Which Might Be Essential for Favorable Functional Outcome. Int J Mol Sci 2018; 19. http://www.ncbi.nlm.nih.gov/pubmed/?term=29642434
  12. Presta V, Figliuzzi I, Citoni B et al. Effects of different statin types and dosages on systolic/diastolic blood pressure: Retrospective analysis of 24-hour ambulatory blood pressure database. Journal of clinical hypertension (Greenwich, Conn.) 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29683251
  13. Harlow KE, Africa JA, Wells A et al. Clinically Actionable Hypercholesterolemia and Hypertriglyceridemia in Children with Nonalcoholic Fatty Liver Disease. J Pediatr 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29661561
  14. Lee Y, Pai SB, Bellamkonda RV et al. Cerivastatin Nano-Liposome as a Potential Disease Modifying Approach for the Treatment of Pulmonary Arterial Hypertension. J Pharmacol Exp Ther 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29695410
  15. McMahon RA, Fletcher JL, Aden JK et al. Preinjury statin use and thromboembolic events in trauma: a 10-year retrospective evaluation. J Surg Res 2018; 226:100-111. http://www.ncbi.nlm.nih.gov/pubmed/?term=29661275
  16. Bajawi SM, Jafarri SA, Buraik MA et al. Pathogenesis-based therapy: Cutaneous abnormalities of CHILD syndrome successfully treated with topical simvastatin monotherapy. JAAD case reports 2018; 4:232-234. http://www.ncbi.nlm.nih.gov/pubmed/?term=29687057
  17. Nguyen S, Chuah SY, Fontas E et al. Atorvastatin in Combination With Narrowband UV-B in Adult Patients With Active Vitiligo: A Randomized Clinical Trial. JAMA dermatology 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29617528
  18. Garrett N, Pombo J, Umpierrez M et al. Pravastatin therapy during preeclampsia prevents long-term adverse health effects in mice. JCI insight 2018; 3. http://www.ncbi.nlm.nih.gov/pubmed/?term=29669946
  19. Patel SS, Guzman L, Lin FP et al. Utilization of Aspirin and Statin in Management of Coronary Artery Disease in Patients with Cirrhosis Undergoing Liver Transplant Evaluation. Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29624871
  20. Kotyla PJ. Simvastatin reduces antiphospholipid antibodies formation in patients with systemic lupus erythematosus: a preliminary study. Lupus 2018:961203318772015. http://www.ncbi.nlm.nih.gov/pubmed/?term=29699441
  21. Ko HHT, Lareu RR, Dix BR, Hughes JD. Statin Use Associated With a Decreased Risk of Community-Acquired Staphylococcus aureus Bacteremia. Mayo Clinic proceedings 2018; 93:541-542. http://www.ncbi.nlm.nih.gov/pubmed/?term=29622101
  22. Smit J, Schonheyder HC, Nielsen H et al. In Reply-Statin Use Associated With a Decreased Risk of Community-Acquired Staphylococcus aureus Bacteremia. Mayo Clinic proceedings 2018; 93:542. http://www.ncbi.nlm.nih.gov/pubmed/?term=29622103
  23. Ekerbicer N, Gurpinar T, Sisman AR et al. Statins reduce testicular and ocular VEGF: A potential compromise to microcirculation. Microvascular research 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29678729
  24. Miranda HF, Sierralta F, Aranda N et al. Antinociception induced by rosuvastatin in murine neuropathic pain. Pharmacological reports : PR 2017; 70:503-508. http://www.ncbi.nlm.nih.gov/pubmed/?term=29660653
  25. Bech AP, Wetzels JFM, Nijenhuis T. Effects of sildenafil, metformin, and simvastatin on ADH-independent urine concentration in healthy volunteers. Physiological reports 2018; 6:e13665. http://www.ncbi.nlm.nih.gov/pubmed/?term=29611351
  26. Ociepka A, Milewicz T, Kialka M, Krzyczkowska-Sendrakowska M. Vascular effects of simvastatin are similar to hormone replacement therapy in postmenopausal women. Przeglad lekarski 2016; 73:280-286. http://www.ncbi.nlm.nih.gov/pubmed/?term=29629740

Primary Prevention

  1. Cesena FHY, Laurinavicius AG, Valente VA et al. Statin Eligibility in Primary Prevention: From a Risk-Based Strategy to a Personalized Approach Based on the Predicted Benefit. Am J Cardiol 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29605080
  2. Muniyappa R, Noureldin RA, Abd-Elmoniem KZ et al. Personalized Statin Therapy and Coronary Atherosclerotic Plaque Burden in Asymptomatic Low/Intermediate-Risk Individuals. Cardiorenal Med 2018; 8:140-150. http://www.ncbi.nlm.nih.gov/pubmed/?term=29617001
  3. Jarmul J, Pletcher MJ, Hassmiller Lich K et al. Cardiovascular Genetic Risk Testing for Targeting Statin Therapy in the Primary Prevention of Atherosclerotic Cardiovascular Disease: A Cost-Effectiveness Analysis. Circ Cardiovasc Qual Outcomes 2018; 11:e004171. http://www.ncbi.nlm.nih.gov/pubmed/?term=29650716
  4. Fentanes E, Vande Hei AG, Holuby RS et al. Treatment in a Preventive Cardiology Clinic Utilizing Advanced Practice Providers (APPs) Effectively Closes Atherosclerotic Cardiovascular Disease (ASCVD) Risk Management Gaps Amongst a Primary Prevention Population Compared with a Propensity-Matched Primary Care Cohort: A Team Based Care Model and its Impact on Lipid and Blood Pressure Management. Clin Cardiol 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29667200

Registry data

  1. Tvaryanas AP, Wagner JH, Maupin GM. Statins and Musculoskeletal Conditions in U.S. Air Force Active Duty Aviators. Aerosp Med Hum Perform 2018; 89:421-427. http://www.ncbi.nlm.nih.gov/pubmed/?term=29673426
  2. Naganuma T, Tsujita K, Mitomo S et al. Impact of Chronic Kidney Disease on Outcomes After Percutaneous Coronary Intervention for Chronic Total Occlusions (from the Japanese Multicenter Registry). Am J Cardiol 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29627112
  3. Aboulnaga S, Mahfouz A, Ewila HA et al. Postoperative Cardiac Surgery Outcomes in a Statin-Native Population. Anesthesia, essays and researches 2018; 12:223-228. http://www.ncbi.nlm.nih.gov/pubmed/?term=29628586
  4. Chen SK, Barbhaiya M, Fischer MA et al. Lipid Testing and Statin Prescription among Medicaid Recipients with Systemic Lupus Erythematosus, Diabetes Mellitus and the General Medicaid Population. Arthritis care & research 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29648687
  5. Rozenbaum Z, Ravid D, Margolis G et al. Association of Pre-Admission Statin Therapy and the Inflammatory Response in ST Elevation Myocardial Infarction patients. Biomarkers 2018:1-19. http://www.ncbi.nlm.nih.gov/pubmed/?term=29620476
  6. Desai P, Wallace R, Anderson ML et al. An analysis of the effect of statins on the risk of Non-Hodgkin's Lymphoma in the Women's Health Initiative cohort. Cancer medicine 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29608241
  7. Fowke JH, Motley SS. Statin Use Linked with a Decrease in the Conversion from High-Grade Prostatic Intraepithelial Neoplasia (HGPIN) to Prostate Cancer. Carcinogenesis 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29617729
  8. Kamran H, Kupferstein E, Sharma N et al. Statins and New-Onset Diabetes in Cardiovascular and Kidney Disease Cohorts: A Meta-Analysis. Cardiorenal Med 2018; 8:105-112. http://www.ncbi.nlm.nih.gov/pubmed/?term=29617000
  9. Umeda T, Hayashi A, Harada A et al. Low-Density Lipoprotein Cholesterol Goal Attainment Rates by Initial Statin Monotherapy Among Patients With Dyslipidemia and High Cardiovascular Risk in Japan- A Retrospective Database Analysis. Circulation journal : official journal of the Japanese Circulation Society 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29628458
  10. Lin FJ, Lin HW, Ho YF. Effect of Statin Intensity on the Risk of Epilepsy After Ischaemic Stroke: Real-World Evidence from Population-Based Health Claims. CNS drugs 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29619760
  11. Danese MD, Sidelnikov E, Kutikova L. The prevalence, low-density lipoprotein cholesterol levels and treatment of patients at very high risk of cardiovascular events in the United Kingdom: a cross-sectional study. Current medical research and opinion 2018:1-15. http://www.ncbi.nlm.nih.gov/pubmed/?term=29627994
  12. Hashiguchi M, Hakamata J, Shimizu M et al. Risk factors for rhabdomyolysis with HMG-CoA reductase inhibitors identified using a postmarketing surveillance database in Japan. International journal of clinical pharmacology and therapeutics 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29701171
  13. Ham SY, Song SW, Nam SB et al. Effects of chronic statin use on 30-day major adverse cardiac and cerebrovascular events after thoracic endovascular aortic repair. J Cardiovasc Surg (Torino) 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29616526
  14. Anderson JL, Knowlton KU, May HT et al. Temporal changes in statin prescription and intensity at discharge and impact on outcomes in patients with newly diagnosed atherosclerotic cardiovascular disease-Real-world experience within a large integrated health care system: The IMPRES study. J Clin Lipidol 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29703626
  15. Khokhar B, Simoni-Wastila L, Slejko JF et al. In-Hospital Mortality Following Traumatic Brain Injury Among Older Medicare Beneficiaries, Comparing Statin Users With Nonusers. The Journal of pharmacy technology : jPT : official publication of the Association of Pharmacy Technicians 2017; 33:225-236. http://www.ncbi.nlm.nih.gov/pubmed/?term=29607441
  16. McMahon RA, Fletcher JL, Aden JK et al. Preinjury statin use and thromboembolic events in trauma: a 10-year retrospective evaluation. J Surg Res 2018; 226:100-111. http://www.ncbi.nlm.nih.gov/pubmed/?term=29661275
  17. Arinze N, Farber A, Sachs T et al. The effect of statin use and intensity on stroke and myocardial infarction after carotid endarterectomy. Journal of vascular surgery 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29685507
  18. Lee SE, Sung JM, Cho IJ et al. Risk of new-onset diabetes among patients treated with statins according to hypertension and gender: Results from a nationwide health-screening cohort. PLoS One 2018; 13:e0195459. http://www.ncbi.nlm.nih.gov/pubmed/?term=29630642
  19. Can A, Castro VM, Dligach D et al. Lipid-Lowering Agents and High HDL (High-Density Lipoprotein) Are Inversely Associated With Intracranial Aneurysm Rupture. Stroke 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29622625

Renal Disease

  1. Naganuma T, Tsujita K, Mitomo S et al. Impact of Chronic Kidney Disease on Outcomes After Percutaneous Coronary Intervention for Chronic Total Occlusions (from the Japanese Multicenter Registry). Am J Cardiol 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29627112
  2. Kamran H, Kupferstein E, Sharma N et al. Statins and New-Onset Diabetes in Cardiovascular and Kidney Disease Cohorts: A Meta-Analysis. Cardiorenal Med 2018; 8:105-112. http://www.ncbi.nlm.nih.gov/pubmed/?term=29617000
  3. Verdoodt A, Honore Pm Md PF, Jacobs R et al. Do Statins Induce or Protect from Acute Kidney Injury and Chronic Kidney Disease: An Update Review in 2018. Journal of translational internal medicine 2018; 6:21-25. http://www.ncbi.nlm.nih.gov/pubmed/?term=29607300
  4. Shen H, Chen X, Lu J et al. Effects of statin therapy on chronic kidney disease patients with coronary artery disease. Lipids Health Dis 2018; 17:84. http://www.ncbi.nlm.nih.gov/pubmed/?term=29665812

Reviews

  1. Braun MM, Stevens WA, Barstow CH. Stable Coronary Artery Disease: Treatment. American family physician 2018; 97:376-384. http://www.ncbi.nlm.nih.gov/pubmed/?term=29671538
  2. Bavishi A, Howard T, Rosen A, Stone NJ. Sudden Creatine Kinase Elevation When an Athlete Starts Boxing: Looking Deeper before Knocking the Statin Out. Am J Med 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29649457
  3. Patel RS, Scopelliti EM, Olugbile O. The Role of PCSK9 Inhibitors in the Treatment of Hypercholesterolemia. The Annals of pharmacotherapy 2018:1060028018771670. http://www.ncbi.nlm.nih.gov/pubmed/?term=29667842
  4. Liang X, He Q, Zhao Q. Effect of Stains on LDL Reduction and Liver Safety: A Systematic Review and Meta-Analysis. BioMed research international 2018; 2018:7092414. http://www.ncbi.nlm.nih.gov/pubmed/?term=29693013
  5. Banach M, Mikhailidis DP. Statin Intolerance: Some Practical Hints. Cardiol Clin 2018; 36:225-231. http://www.ncbi.nlm.nih.gov/pubmed/?term=29609752
  6. Bin Abdulhak AA, Robinson JG. Optimizing Statins and Ezetimibe in Guideline-Focused Management. Cardiol Clin 2018; 36:221-223. http://www.ncbi.nlm.nih.gov/pubmed/?term=29609751
  7. Nelson AJ, Nicholls SJ. Treating Dyslipidemia in Type 2 Diabetes. Cardiol Clin 2018; 36:233-239. http://www.ncbi.nlm.nih.gov/pubmed/?term=29609753
  8. Saeed A, Ballantyne CM. Bempedoic Acid (ETC-1002): A Current Review. Cardiol Clin 2018; 36:257-264. http://www.ncbi.nlm.nih.gov/pubmed/?term=29609755
  9. Kamran H, Kupferstein E, Sharma N et al. Statins and New-Onset Diabetes in Cardiovascular and Kidney Disease Cohorts: A Meta-Analysis. Cardiorenal Med 2018; 8:105-112. http://www.ncbi.nlm.nih.gov/pubmed/?term=29617000
  10. Muniyappa R, Noureldin RA, Abd-Elmoniem KZ et al. Personalized Statin Therapy and Coronary Atherosclerotic Plaque Burden in Asymptomatic Low/Intermediate-Risk Individuals. Cardiorenal Med 2018; 8:140-150. http://www.ncbi.nlm.nih.gov/pubmed/?term=29617001
  11. Aday AW, Everett BM. Statins in Peripheral Artery Disease: What Are We Waiting For? Circulation 2018; 137:1447-1449. http://www.ncbi.nlm.nih.gov/pubmed/?term=29610126
  12. Fentanes E, Vande Hei AG, Holuby RS et al. Treatment in a Preventive Cardiology Clinic Utilizing Advanced Practice Providers (APPs) Effectively Closes Atherosclerotic Cardiovascular Disease (ASCVD) Risk Management Gaps Amongst a Primary Prevention Population Compared with a Propensity-Matched Primary Care Cohort: A Team Based Care Model and its Impact on Lipid and Blood Pressure Management. Clin Cardiol 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29667200
  13. Munkhaugen J, Otterstad JE, Dammen T et al. The prevalence and predictors of elevated C-reactive protein after a coronary heart disease event. Eur J Prev Cardiol 2018:2047487318768940. http://www.ncbi.nlm.nih.gov/pubmed/?term=29635941
  14. Sessa M, Rafaniello C, Scavone C et al. Preventable statin adverse reactions and therapy discontinuation. What can we learn from the spontaneous reporting system? Expert opinion on drug safety 2018:1-9. http://www.ncbi.nlm.nih.gov/pubmed/?term=29619841
  15. Maierean SM, Mikhailidis DP, Toth PP et al. The potential role of statins in preeclampsia and dyslipidemia during gestation: a narrative review. Expert opinion on investigational drugs 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29672173
  16. Verdoodt A, Honore Pm Md PF, Jacobs R et al. Do Statins Induce or Protect from Acute Kidney Injury and Chronic Kidney Disease: An Update Review in 2018. Journal of translational internal medicine 2018; 6:21-25. http://www.ncbi.nlm.nih.gov/pubmed/?term=29607300
  17. Shen H, Chen X, Lu J et al. Effects of statin therapy on chronic kidney disease patients with coronary artery disease. Lipids Health Dis 2018; 17:84. http://www.ncbi.nlm.nih.gov/pubmed/?term=29665812

Safety and side effects

  1. Tvaryanas AP, Wagner JH, Maupin GM. Statins and Musculoskeletal Conditions in U.S. Air Force Active Duty Aviators. Aerosp Med Hum Perform 2018; 89:421-427. http://www.ncbi.nlm.nih.gov/pubmed/?term=29673426
  2. Bavishi A, Howard T, Rosen A, Stone NJ. Sudden Creatine Kinase Elevation When an Athlete Starts Boxing: Looking Deeper before Knocking the Statin Out. Am J Med 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29649457
  3. Aboulnaga S, Mahfouz A, Ewila HA et al. Postoperative Cardiac Surgery Outcomes in a Statin-Native Population. Anesthesia, essays and researches 2018; 12:223-228. http://www.ncbi.nlm.nih.gov/pubmed/?term=29628586
  4. Liang X, He Q, Zhao Q. Effect of Stains on LDL Reduction and Liver Safety: A Systematic Review and Meta-Analysis. BioMed research international 2018; 2018:7092414. http://www.ncbi.nlm.nih.gov/pubmed/?term=29693013
  5. Liang E, Rastegar M. Immune-mediated necrotising myopathy: a rare cause of hyperCKaemia. BMJ case reports 2018; 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29691272
  6. Kruger K, Leppkes N, Gehrke-Beck S et al. Improving long-term adherence to statin therapy: a qualitative study of GPs' experiences in primary care. Br J Gen Pract 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29686133
  7. Kamran H, Kupferstein E, Sharma N et al. Statins and New-Onset Diabetes in Cardiovascular and Kidney Disease Cohorts: A Meta-Analysis. Cardiorenal Med 2018; 8:105-112. http://www.ncbi.nlm.nih.gov/pubmed/?term=29617000
  8. Wang N, Lu Y, Wang K et al. Simvastatin Attenuates Neurogenetic Damage and Improves Neurocongnitive Deficits Induced by Isoflurane in Neonatal Rats. Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology 2018; 46:618-632. http://www.ncbi.nlm.nih.gov/pubmed/?term=29617679
  9. Park HS, Gu JY, Yoo HJ et al. Thrombin Generation Assay Detects Moderate-Intensity Statin-Induced Reduction of Hypercoagulability in Diabetes. Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis 2018:1076029618766254. http://www.ncbi.nlm.nih.gov/pubmed/?term=29669440
  10. Dare RK, Tewell C, Harris B et al. Statin Coadministration Increases the Risk of Daptomycin-Associated Myopathy. Clin Infect Dis 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29668884
  11. McKeand W, Baird-Bellaire S, Ermer J, Patat A. A Study of the Potential Interaction Between Bazedoxifene and Atorvastatin in Healthy Postmenopausal Women. Clinical pharmacology in drug development 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29683561
  12. Jonnalagadda VG, Shaik A. Statin on insulin and adiponectin levels: true or false prophecy? Diabetes, metabolic syndrome and obesity : targets and therapy 2018; 11:131. http://www.ncbi.nlm.nih.gov/pubmed/?term=29697702
  13. Kim H, Choi HY, Kim YH et al. Pharmacokinetic interactions and tolerability of rosuvastatin and ezetimibe: an open-label, randomized, multiple-dose, crossover study in healthy male volunteers. Drug design, development and therapy 2018; 12:815-821. http://www.ncbi.nlm.nih.gov/pubmed/?term=29692602
  14. Lee J, Rhee SJ, Lee S, Yu KS. Evaluation of drug interactions between fimasartan and rosuvastatin after single and multiple doses in healthy Caucasians. Drug design, development and therapy 2018; 12:787-794. http://www.ncbi.nlm.nih.gov/pubmed/?term=29670335
  15. Sessa M, Rafaniello C, Scavone C et al. Preventable statin adverse reactions and therapy discontinuation. What can we learn from the spontaneous reporting system? Expert opinion on drug safety 2018:1-9. http://www.ncbi.nlm.nih.gov/pubmed/?term=29619841
  16. Hashiguchi M, Hakamata J, Shimizu M et al. Risk factors for rhabdomyolysis with HMG-CoA reductase inhibitors identified using a postmarketing surveillance database in Japan. International journal of clinical pharmacology and therapeutics 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29701171
  17. Farrag SM, Hamzawy MA, El-Yamany MF et al. Atorvastatin in nano-particulate formulation abates muscle and liver affliction when coalesced with coenzyme Q10 and/or vitamin E in hyperlipidemic rats. Life sciences 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29694831
  18. Mitchell D, Guertin JR, Dubois A et al. A Discrete Event Simulation Model to Assess the Economic Value of a Hypothetical Pharmacogenomics Test for Statin-Induced Myopathy in Patients Initiating a Statin in Secondary Cardiovascular Prevention. Molecular diagnosis & therapy 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29651791
  19. Sadeeqa S, Maqsood M, Ahmad M. Prevalence of statin induced myopathy in Lahore, Pakistan. Pak J Pharm Sci 2018; 31:617-622. http://www.ncbi.nlm.nih.gov/pubmed/?term=29625933
  20. Lee SE, Sung JM, Cho IJ et al. Risk of new-onset diabetes among patients treated with statins according to hypertension and gender: Results from a nationwide health-screening cohort. PLoS One 2018; 13:e0195459. http://www.ncbi.nlm.nih.gov/pubmed/?term=29630642
  21. Momo K, Takagi A, Miyaji A, Koinuma M. Assessment of statin-induced interstitial pneumonia in patients treated for hyperlipidemia using a health insurance claims database in Japan. Pulmonary pharmacology & therapeutics 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29627482
  22. Matsubara A, Oda S, Akai S et al. Establishment of a drug-induced rhabdomyolysis mouse model by co-administration of ciprofloxacin and atorvastatin. Toxicology letters 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29679711

Stroke and CNS

  1. Arinze N, Farber A, Sachs T et al. The effect of statin use and intensity on stroke and myocardial infarction after carotid endarterectomy. Journal of vascular surgery 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29685507
  2. Wang N, Lu Y, Wang K et al. Simvastatin Attenuates Neurogenetic Damage and Improves Neurocongnitive Deficits Induced by Isoflurane in Neonatal Rats. Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology 2018; 46:618-632. http://www.ncbi.nlm.nih.gov/pubmed/?term=29617679
  3. Lin FJ, Lin HW, Ho YF. Effect of Statin Intensity on the Risk of Epilepsy After Ischaemic Stroke: Real-World Evidence from Population-Based Health Claims. CNS drugs 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29619760
  4. Khokhar B, Simoni-Wastila L, Slejko JF et al. In-Hospital Mortality Following Traumatic Brain Injury Among Older Medicare Beneficiaries, Comparing Statin Users With Nonusers. The Journal of pharmacy technology : jPT : official publication of the Association of Pharmacy Technicians 2017; 33:225-236. http://www.ncbi.nlm.nih.gov/pubmed/?term=29607441
  5. Ham SY, Song SW, Nam SB et al. Effects of chronic statin use on 30-day major adverse cardiac and cerebrovascular events after thoracic endovascular aortic repair. J Cardiovasc Surg (Torino) 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29616526
  6. Can A, Castro VM, Dligach D et al. Lipid-Lowering Agents and High HDL (High-Density Lipoprotein) Are Inversely Associated With Intracranial Aneurysm Rupture. Stroke 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29622625

Triglycerides/HDL

  1. Yamashita M, Iwata A, Kato Y et al. Impact of the triglyceride level on coronary plaque components in female patients with coronary artery disease treated with statins. Heart Vessels 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29696358
  2. Wei WQ, Li X, Feng Q et al. LPA Variants are Associated with Residual Cardiovascular Risk in Patients Receiving Statins. Circulation 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29703846
  3. Takata K, Kataoka Y, Andrews J et al. Triglyceride-to-High-Density Lipoprotein Cholesterol Ratio and Vulnerable Plaque Features With Statin Therapy in Diabetic Patients With Coronary Artery Disease: Frequency-Domain Optical Coherence Tomography Analysis. JACC. Cardiovascular imaging 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29680344
  4. Ridker PM, Rose LM, Kastelein JJP et al. Cardiovascular event reduction with PCSK9 inhibition among 1578 patients with familial hypercholesterolemia: Results from the SPIRE randomized trials of bococizumab. J Clin Lipidol 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29685591
  5. Toth PP, Jones SR, Slee A et al. Relationship between lipoprotein subfraction cholesterol and residual risk for cardiovascular outcomes: A post hoc analysis of the AIM-HIGH trial. J Clin Lipidol 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29627296
  6. Vallejo-Vaz AJ, Fayyad R, Boekholdt SM et al. Triglyceride-Rich Lipoprotein Cholesterol and Risk of Cardiovascular Events Among Patients Receiving Statin Therapy in the Treating to New Targets (TNT) Trial. Circulation 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29618599
  7. Can A, Castro VM, Dligach D et al. Lipid-Lowering Agents and High HDL (High-Density Lipoprotein) Are Inversely Associated With Intracranial Aneurysm Rupture. Stroke 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29622625

Trials

  1. Wu Z, Camargo CA, Jr., Khaw KT et al. Effects of vitamin D supplementation on adherence to and persistence with long-term statin therapy: Secondary analysis from the randomized, double-blind, placebo-controlled ViDA study. Atherosclerosis 2018; 273:59-66. http://www.ncbi.nlm.nih.gov/pubmed/?term=29684661
  2. Wang K, Chen L, Liu L et al. The effects of atorvastatin on IL-6, CRP, blood lipid and myocardial protection of interventional therapy in patients with acute myocardial infarction. Minerva medica 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29696937
  3. Presta V, Figliuzzi I, Citoni B et al. Effects of different statin types and dosages on systolic/diastolic blood pressure: Retrospective analysis of 24-hour ambulatory blood pressure database. Journal of clinical hypertension (Greenwich, Conn.) 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29683251
  4. Kato Y, Iwata A, Futami M et al. Impact of von Willebrand factor on coronary plaque burden in coronary artery disease patients treated with statins. Medicine (Baltimore) 2018; 97:e0589. http://www.ncbi.nlm.nih.gov/pubmed/?term=29703054
  5. Haddad C, Hallit S, Salhab M et al. Association Between Adherence to Statins, Illness Perception, Treatment Satisfaction, and Quality of Life among Lebanese patients. Journal of cardiovascular pharmacology and therapeutics 2018:1074248418769635. http://www.ncbi.nlm.nih.gov/pubmed/?term=29683005
  6. Gauthier MS, Awan Z, Bouchard A et al. Posttranslational modification of proprotein convertase subtilisin/kexin type 9 is differentially regulated in response to distinct cardiometabolic treatments as revealed by targeted proteomics. J Clin Lipidol 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29699916
  7. Gant CM, Binnenmars SH, Harmelink M et al. Real-life achievement of lipid-lowering treatment targets in the DIAbetes and LifEstyle Cohort Twente: systemic assessment of pharmacological and nutritional factors. Nutrition & diabetes 2018; 8:24. http://www.ncbi.nlm.nih.gov/pubmed/?term=29695715
  8. Arinze N, Farber A, Sachs T et al. The effect of statin use and intensity on stroke and myocardial infarction after carotid endarterectomy. Journal of vascular surgery 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29685507
  9. Welnicki M, Sliz D, Filipiak KJ et al. [Difference in efficacy of dyslipidaemia treatment in obese and not obese women. Analysis of date from 3ST-POL study]. Przeglad lekarski 2016; 73:353-358. http://www.ncbi.nlm.nih.gov/pubmed/?term=29668197
  10. Oh GC, Han JK, Han KH et al. Efficacy and Safety of Fixed-dose Combination Therapy With Telmisartan and Rosuvastatin in Korean Patients With Hypertension and Dyslipidemia: TELSTA-YU (TELmisartan-rosuvaSTAtin from YUhan), a Multicenter, Randomized, 4-Arm, Double-blind, Placebo-controlled, Phase III Study. Clinical therapeutics 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29673890
  11. Toth PP, Jones SR, Slee A et al. Relationship between lipoprotein subfraction cholesterol and residual risk for cardiovascular outcomes: A post hoc analysis of the AIM-HIGH trial. J Clin Lipidol 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29627296
  12. Berwanger O, de Barros ESPGM, Dall Orto FTC et al. Rationale and design of the Statins Evaluation in Coronary procedUres and REvascularization: The SECURE-PCI Trial. Am Heart J 2018; 198:129-134. http://www.ncbi.nlm.nih.gov/pubmed/?term=29653634
  13. Vallejo-Vaz AJ, Fayyad R, Boekholdt SM et al. Triglyceride-Rich Lipoprotein Cholesterol and Risk of Cardiovascular Events Among Patients Receiving Statin Therapy in the Treating to New Targets (TNT) Trial. Circulation 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29618599
  14. Singh K, Crossan C, Laba TL et al. Cost-effectiveness of a fixed dose combination (polypill) in secondary prevention of cardiovascular diseases in India: Within-trial cost-effectiveness analysis of the UMPIRE trial. Int J Cardiol 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29622506
  15. Sadeeqa S, Maqsood M, Ahmad M. Prevalence of statin induced myopathy in Lahore, Pakistan. Pak J Pharm Sci 2018; 31:617-622. http://www.ncbi.nlm.nih.gov/pubmed/?term=29625933
  16. Masaki N, Kumagai K, Sasaki K et al. Suppressive effect of pitavastatin on aortic arch dilatation in acute stanford type B aortic dissection: analysis of STANP trial. General thoracic and cardiovascular surgery 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29626287
  17. Liu Y, Song X, Zhou H et al. Gut Microbiome Associates With Lipid-Lowering Effect of Rosuvastatin in Vivo. Frontiers in microbiology 2018; 9:530. http://www.ncbi.nlm.nih.gov/pubmed/?term=29623075
  18. Lee TC, Kaouache M, Grover SA. Evaluation of the cost-effectiveness of evolocumab in the FOURIER study: a Canadian analysis. CMAJ open 2018; 6:E162-e167. http://www.ncbi.nlm.nih.gov/pubmed/?term=29622685
  19. Itoh H, Komuro I, Takeuchi M et al. Intensive Treat-to-Target Statin Therapy in High-Risk Japanese Patients With Hypercholesterolemia and Diabetic Retinopathy: Report of a Randomized Study. Diabetes Care 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29626074

Women and elderly

  1. Yamashita M, Iwata A, Kato Y et al. Impact of the triglyceride level on coronary plaque components in female patients with coronary artery disease treated with statins. Heart Vessels 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29696358
  2. McKeand W, Baird-Bellaire S, Ermer J, Patat A. A Study of the Potential Interaction Between Bazedoxifene and Atorvastatin in Healthy Postmenopausal Women. Clinical pharmacology in drug development 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29683561
  3. Welnicki M, Sliz D, Filipiak KJ et al. [Difference in efficacy of dyslipidaemia treatment in obese and not obese women. Analysis of date from 3ST-POL study]. Przeglad lekarski 2016; 73:353-358. http://www.ncbi.nlm.nih.gov/pubmed/?term=29668197
  4. Volgman AS, Dembowski E, Braun LT. Should Sex Matter When it Comes to High-Intensity Statins? J Am Coll Cardiol 2018; 71:1738-1740. http://www.ncbi.nlm.nih.gov/pubmed/?term=29673464
  5. Strandberg TE, Urtamo A, Kahara J et al. Statin Treatment Is Associated With a Neutral Effect on Health-Related Quality of Life Among Community-Dwelling Octogenarian Men. J Gerontol A Biol Sci Med Sci 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29659717
  6. Peters SAE, Colantonio LD, Zhao H et al. Sex Differences in High-Intensity Statin Use Following Myocardial Infarction in the United States. J Am Coll Cardiol 2018; 71:1729-1737. http://www.ncbi.nlm.nih.gov/pubmed/?term=29673463
  7. Ofori-Asenso R, Llomaki J, Tacey M et al. Patterns of Statin Use and Long-term Adherence and Persistence among Older Adults with Diabetes. Journal of diabetes 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29658177
  8. Maierean SM, Mikhailidis DP, Toth PP et al. The potential role of statins in preeclampsia and dyslipidemia during gestation: a narrative review. Expert opinion on investigational drugs 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29672173
  9. Garrett N, Pombo J, Umpierrez M et al. Pravastatin therapy during preeclampsia prevents long-term adverse health effects in mice. JCI insight 2018; 3. http://www.ncbi.nlm.nih.gov/pubmed/?term=29669946
  10. Ociepka A, Milewicz T, Kialka M, Krzyczkowska-Sendrakowska M. Vascular effects of simvastatin are similar to hormone replacement therapy in postmenopausal women. Przeglad lekarski 2016; 73:280-286. http://www.ncbi.nlm.nih.gov/pubmed/?term=29629740
  11. Huai J, Yang Z, Yi YH et al. [Regulation of pravastatin on long-chain fatty acid oxidative enzyme in pre-eclampsia-like mouse model]. Zhonghua fu chan ke za zhi 2018; 53:183-189. http://www.ncbi.nlm.nih.gov/pubmed/?term=29609233
  12. Desai P, Wallace R, Anderson ML et al. An analysis of the effect of statins on the risk of Non-Hodgkin's Lymphoma in the Women's Health Initiative cohort. Cancer medicine 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29608241
 
 

Twitter
IAS Website
For information
You are now on the editors mailing list of the IAS Statin Newsletter.
The IAS Statin Newsletter is part of the IAS News and Literature update service.
 
This activity is supported by an educational grant from Pfizer.